An observational study in Kidney Disease, sponsored by Western Sydney Local Health District. Enrolling by invitation at 4 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Western Sydney Local Health District · Observational
To establish a prospective, longitudinal cohort of participants who can provide blood, tissue (including kidney histology), urine samples to establish a core biobank for kidney disease research. Results from this biobank will be matched to clinical outcomes to facilitate the discovery (and/or validation) of novel prognostic, predictive or diagnostic biomarkers important for kidney disease.
Hypothesis:
Genetic ancestry influences the enrichment of certain polymorphisms, which may have important protective or adverse effects on important kidney related outcomes, including developing chronic kidney disease, progression to kidney failure, and/or poor long-term outcomes following kidney transplantation.
Aims:
To establish a prospective, longitudinal cohort of participants who can provide blood, tissue (including kidney histology), urine samples to establish a core biobank for kidney disease research. Results from this biobank will be matched to clinical outcomes to facilitate the discovery (and/or validation) of novel prognostic, predictive or diagnostic biomarkers important for kidney disease. Data from this cohort will be used to determine if genomic factors independently influence:
969 studies on the registry are indexed under Kidney Diseases; 183 are open to participants now.
This study's planned enrollment of 500 is above the median of 245 across 277 observational studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Western Sydney Local Health District is the lead sponsor of 36 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Australian participants - health and kidney disease (groups described earlier)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
eGFR \> 60ml/min/1.73m2, UACR \< 3 mg/mmol (or UPCR \< 10 mg/mmol) Has risk factors for kidney disease, including any of the following: Family history of kidney disease (CKD, dialysis or transplant) Any history of acute kidney injury or eGFR decline from baseline Established diabetes, hypertension, stroke, heart disease or heart failure Current or ex-smoker, overweight (BMI \> 25) or obesity (BMI \> 30)
eGFR ≤ 60ml/min/1.73m2 (over minimum 3-month period), or UACR \> 30mg/mmol (or PCR \> 100mg/mmol). CKD can be from any cause/aetiology.
Patients established on peritoneal dialysis or haemodialysis for at least 3 months
Development of CKD
Group 1 develops eGFR ≤ 60ml/min/1.73m2 (or biopsy proven kidney disease) ≥ 3-months, or albuminuria or proteinuria (UACR \> 3mg/mmol or UPCR \> 10mg/mmol) ≥ 3-months
Time frame: 20 years
Progression of CKD
For group 2, defined by eGFR decline ≥ 30% from baseline for ≥ 3 months, or eGFR decline to below 15ml/min/1.73m2 if baseline eGFR \> 30ml/min/1.73m2, or the need for renal replacement therapy
Time frame: 20 years
Removal from dialysis
For group 3 - either death (survival time on dialysis) if they do not receive a kidney transplant during the study, or if they receive a kidney transplant
Time frame: 20 years
Death
death from any cause
Time frame: 20 years
Hospital Admissions
Hospital or emergency department visits for any reason
Time frame: 20 years
estimated glomerular filtration rate slope
change in eGFR over time
Time frame: 10 and 20 year time points
Cardiovascular event or major risk factors
(MACE): non-fatal stroke, non-fatal myocardial infarction, cardiovascular death. Major risk factors: diabetes mellitus, dyslipidaemia, obesity, hypertension
Time frame: 20 years
Major infectious events
bacterial, fungal or viral infection which necessitates hospital admission or medical attention
Time frame: 20 years
Malignancy
any cancer diagnosis following enrolment
Time frame: 20 years
acute kidney episodes
acute kidney episodes (defined by KDIGO criteria), registry code or clinician assignment for group 1 or 2
Time frame: 20 years
Dialysis dose
time on dialysis (hours/days) and dialysis prescription (if available)
Time frame: 10 years
Plan to share: No — Confidential information and data sharing requires additional ethics submission or individual participant consent
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Western Sydney Local Health District